The growth
of the overall Patient Derived Xenograft Models Market can be
attributed to the growing demand for personalized medicine, continuous support
for cancer research from the public as well as private sectors, and growth in
the number of R&D activities in the pharmaceutical industry. In the coming
years, North America is expected to account for the largest share of the global
market.
The global PDX models market is expected to
reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of
16.7%.
PDX Models Market: Impact Analysis
1. Growth in the Number of Pharmaceutical R&D Activities
2. Cancer Research
3. Growing Demand for Personalized Medicine
4. Rising Demand for Humanized PDX Models
5. Regional Snapshot of the Global Patient Derived Xenograft Models Market
Key Questions Addressed in The Report:
1. Who are the top 10
players operating in the global Adhesion Barrier market?
2. What are the drivers, restraints, opportunities, and challenges in the
Adhesion Barrier Industry?
3. What are the opportunities for stakeholders and provide details of the
competitive landscape for key players?
4. What will be growth of Adhesion Barrier in North America, Europe, Asia
Pacific, Latin America, and the Middle East and Africa?
5. What are the Known and
Unknown Adjacencies Impacting the Patient Derived Xenograft/PDX Models Market?
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Type of PDX Models:
The
mice models segment is estimated to command the largest share of the global
market in 2017. The rat models segment, on the other hand, is projected to
register the highest CAGR from 2017 to 2022. Growth in this market is mainly
driven by the larger size of rats, which enhances surgical manipulation. The
development of immunodeficient rats will drive the usage of rat models in PDX
model generation.
Tumor Type:
Based on tumor type, the PDX models market has been segmented into
gastrointestinal tumor models, gynecological tumor models, respiratory tumor
models, urological tumor models, hematological tumor models, and other tumor
models such as head & neck tumors, sarcoma, and melanoma. In 2017, the
gastrointestinal tumor models segment is expected to account for the largest
share of the global market.
Pre-Clinical Drug Development and Cancer Research Application:
The preclinical drug development and basic cancer research segment is
expected to account for the largest share of the global patient derived
xenograft models market. Growth in this segment is mainly driven by the
increasing number of research activities in the field of oncology drug
research.
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Key Players:
The various
players in the global PDX models industry include
Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US),
The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories
International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech
Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead
(France), and Explora BioLabs (US).
Crown Bioscience Inc. is one of the strongest players in the
PDX models market, having facilities across the US, the UK, China, and Taiwan.
The company focuses on discovering new oncology drugs and is continuously
expanding its PDX models bank to recapitulate the diversity and complexity of
human cancer biology in the laboratory. The company is strongly engaged in
organic and inorganic growth strategies like expansions and
agreements/partnerships/collaborations, respectively.
Comments
Post a Comment